Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition

PLoS ONE

Volumn 3, Issue 2, 2008, Pages

  Jones, R Brad ^a   Garrison, Keith E ^b   Wong, Jessica C ^a   Duan, Erick H ^a   Nixon, Douglas F ^b   Ostrowski, Mario A ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ENHANCED GREEN FLUORESCENT PROTEIN; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; NUCLEOSIDE;

3' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVE SITE; ENZYME BINDING; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LONG INTERSPERSED REPEAT; RETROPOSON; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; DRUG TOXICITY; GENETICS; GENOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

DRUG EVALUATION; DRUG TOXICITY; GENOME, HUMAN; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; NUCLEOSIDES; RETROELEMENTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 45249124072     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001547     Document Type: Article

References (45)

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921.
2. Sassaman DM, Dombroski BA, Moran JV, Kimberland ML, Naas TP, et al. (1997) Many human L1 elements are capable of retrotransposition. Nat Genet 16: 37-43.
3. Brouha B, Schustak J, Badge RM, Lutz-Prigge S, Farley AH, et al. (2003) Hot L1s account for the bulk of retrotransposition in the human population. Proc Natl Acad Sci U S A 100: 5280-5285.
4. Martin SL (2006) The ORF1 Protein Encoded by LINE-1: Structure and Function During L1 Retrotransposition. J Biomed Biotechnol 2006: 45621.
5. Basame S, Wai-lun Li P, Howard G, Branciforte D, Keller D, et al. (2006) Spatial assembly and RNA binding stoichiometry of a LINE-1 protein essential for retrotransposition. J Mol Biol 357: 351-357.
6. Martin SL, Branciforte D, Keller D, Bain DL (2003) Trimeric structure for an essential protein in L1 retrotransposition. Proc Natl Acad Sci U S A 100: 13815-13820.
7. Martin SL, Cruceanu M, Branciforte D, Wai-Lun Li P, Kwok SC, et al. (2005) LINE-1 retrotransposition requires the nucleic acid chaperone activity of the ORF1 protein. J Mol Biol 348: 549-561.
8. Martin SL, Bushman FD (2001) Nucleic acid chaperone activity of the ORF1 protein from the mouse LINE-1 retrotransposon. Mol Cell Biol 21: 467-475.
9. Martin SL, Li J, Weisz JA (2000) Deletion analysis defines distinct functional domains for protein-protein and nucleic acid interactions in the ORF1 protein of mouse LINE-1. J Mol Biol 304: 11-20.
10. Hohjoh H, Singer MF (1997) Sequence-specific single-strand RNA binding protein encoded by the human LINE-1 retrotransposon. Embo J 16: 6034-6043.
11. Feng Q, Moran JV, Kazazian HH Jr, Bocke JD (1996) Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. Cell 87: 905-916.
12. Moran JV, Holmes SE, Naas TP, DeBerardinis RJ, Boeke JD, et al. (1996) High frequency retrotransposition in cultured mammalian cells. Cell 87: 917-927.
13. Kolosha VO, Martin SL (1997) In vitro properties of the first ORF protein from mouse LINE-1 support its role in ribonucleoprotein particle formation during retrotransposition. Proc Natl Acad Sci U S A 94: 10155-10160.
14. Cost GJ, Frog Q, Jacquier A, Boeke JD (2002) Human L1 element target-primed reverse transcription in vitro. Embo J 21: 5899-5910.
15. Szak ST, Pickeral OK, Makalowski W, Boguski MS, Landsman D, et al. (2002) Molecular archeology of L1 insertions in the human genome. Genome Biol 3: research0052.
16. Jurka J (1997) Sequence patterns indicate an enzymatic involvement in integration of mammalian retroposons. Proc Natl Acad Sci U S A 94: 1872-1877.
17. Kazazian HH Jr, Wong C, Youssoufian H, Scott AF, Phillips DG, et al. (1988) Haemophilia A resulting from de novo insertion of L1 sequences represents a novel mechanism for mutation in man. Nature 332: 164-166.
18. van den Hurk JA, Meij IC, Seleme MC, Kano H, Nikopoulos K, et al. (2007) L1 retrotransposition can occur early in human embryonic development. Hum Mol Genet 16: 1587-1592.
19. Meischl C, Boer M, Ahlin A, Roos D (2000) A new exon created by intronic insertion of a rearranged LINE-1 element as the cause of chronic granulomatous disease. Eur J Hum Genet 8: 697-703.
20. Musova Z, Hedvicakova P, Mohrmann M, Tesarova M, Krepelova A, et al. (2006) A novel insertion of a rearranged L1 element in exon 44 of the dystrophin gene: further evidence for possible bias in retroposon integration. Biochem Biophys Res Commun-347: 145-149.
21. Narita N, Nishio H, Kitoh Y, Ishikawa Y, Minami R, et al. (1993) Insertion of a 5′ truncated L1 element into the 3′ end of exon 44 of the dystrophin gene resulted in skipping of the exon during splicing in a case of Duchenne muscular dystrophy. J Clin Invest 91: 1862-1867.
22. Kubo S, Seleme MC, Soifer HS, Perez JL, Moran JV, et al. (2006) L1 retrotransposition in nondividing and primary human somatic cells. Proc Natl Acad Sci U S A, 103: 8036-8041.
23. Miki Y, Nishisho I, Horii A, Miyoshi Y, Utsunomiya J, et al. (1992) Disruption of the APC gene by a retrotransposal insertion of L1 sequence in a colon cancer. Cancer Res 52: 643-645.
24. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, et al. (2005) Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24: 7213-7223.
25. Muotri AR, Chu VT, Marchetto MC, Deng W, Moran JV, et al. (2005) Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition. Nature 435: 903-910.
26. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, et al. (1985) 3′ -Azido-3′ -deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 82: 7096-7100.
27. Prescott LM (1995) Lamivudine useful against hepatitis B-HIV co-infection. J Int Assoc Physicians AIDS Care 1: 34.
28. Xie H, Voronkov M, Liotta DC, Korba BA, Schinazi RE, et al. (1995) Phosphatidyl-2′, 3′-dideoxy-3′-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells. Antiviral Res 28: 113-120.
29. Ostertag EM, Prak ET, DeBerardinis RJ, Moran JV, Kazazian HH Jr (2000) Determination of L1 retrotransposition kinetics in cultured cells. Nucleic Acids Res 28: 1418-1423.
30. Heidmann T, Heidmann O, Nicolas JF (1988) An indicator gene to demonstrate intracellular transposition of defective retroviruses. Proc Natl Acad Sci U S A 85: 2219-2223.
31. Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chirino AJ, et al. (1994) Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 91: 3911-3915.
32. Spence RA, Kati WM, Anderson KS, Johnson KA (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267: 988-993.
33. Mangiacasale R, Pittoggi C, Scianianna I, Careddu A, Mattei E, et al. (2003) Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation. Oncogene 22: 2750-2761.
34. Bristol-MyersSquibb (2006) Zerit (Stavudine). Princeton.
35. GlaxoSmithKIine (2001) Epivir Prescribing Information. Research Triangle Park, pp. Epivir Prescribing Information.
36. Drew RH, Weller S, Gallis HA, Walmer KA, Bartlett JA, et al. (1989) Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 33: 1801-1803.
37. GlaxoSmithKline (2001) Retrovir Prescribing Information. Research Triangle Park.
38. GileadSciences (2007) Viread.
39. Cherry CL, Nolan D, James IR, McKinnon EJ, Mallal SA, et al. (2006) Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J Acquir Immune Defic Syndr 42: 435-440.
40. Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, et al. (2003) Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. Aids 17: 1769-1785.
41. Bawdon RE, Kaul S, Sobhi S (1994) Tne ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. Gynecol Obstet Invest 38: 1-4.
42. Bloom SL, Dias KM, Bawdon RE, Gilstrap LC 3rd (1997) The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am J Obstet Gynecol 176: 291-293.
43. Chappuy H, Treluyer JM, Jullien V, Dimet J, Rey E, et al. (2004) Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 48: 4332-4336.
44. Mandelbrot L, Peytavin G, Firtion G, Farinotti R (2001) Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol 184: 153-158.
45. Patterson TA, Binienda ZK, Newport GD, Lipe GW, Gillam MP, et al. (2000) Transplacental pharmacokinetics and fetal distribution of 2′, 3′-didehydro-3′-deoxythymidine (d4T) and its metabolites in late-term rhesus macaques. Teratology 62: 93-99.